MedMen in brief
MedMen is a listed company, based in Los Angeles, USA. In the year to June 2022 it had sales of $141 M and a net profit of $211 M. Its shares trade under the symbol MMNWF (OTC Markets Group).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About MedMen
MedMen Enterprises was a United States-based cannabis company. At its peak, it had operations in California, Nevada, Arizona, Florida, Illinois, New York, and Massachusetts. MedMen owns and operates 29 retail stores and 6 cultivation facilities and is currently licensed to expand its footprint to 65 retail locations. Its stock began trading on the Canadian Securities Exchange under the ticker symbol MMEN in 2018. The CSE suspended trading of MedMen's stocks on January 8, 2024 pursuant to cease trade orders from the Ontario Securities Commission and British Columbia Securities Commission, and the stocks were delisted on May 16, 2024. MedMen was also traded over-the-counter in the United States under the ticker symbol MMNFF. MedMen is based in Culver City, California and has more than 1,000 employees.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
MedMen timeline
- 2019
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
Events of MedMen from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
Not enough history yet.
Key ratios
- P/E ratio (TTM)
- —
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- 149.8%
- Operating margin
- -120.0%
- Return on equity
- 131.9%
- Liabilities / assets
- 198.3%
- Revenue growth
- +6.5%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Jun 2022 | $141M | +6.5% | $-169M | $211M | 149.8% |
| Jun 2021 | $132M | -14.8% | $-55M | $158M | 119.2% |
| Jun 2020 | $155M | — | $-432M | $527M | 339.1% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Jun 2022 | $-63M | $9M | $-72M | — | — |
| Jun 2021 | $-59M | $3M | $-62M | — | — |
| Jun 2020 | $-110M | $57M | $-167M | — | — |
SEC filings
- Jan 30, 20248-KCurrent reportDirectors or officers changed
- Jan 24, 20248-KCurrent reportDirectors or officers changed · Regulation FD disclosure · Other events
- Jan 12, 20248-KCurrent reportAcquisition or disposal completed · Regulation FD disclosure · Other events
- Dec 22, 20238-KCurrent reportMaterial agreement · Regulation FD disclosure
- Oct 2, 20238-KCurrent reportDirectors or officers changed
- Jul 11, 20238-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Jul 10, 202310-QQuarterly report · period to Mar 2023
- Jun 20, 20238-KCurrent reportDirectors or officers changed · Other events
- May 26, 20238-KCurrent reportResults of operations
- May 22, 20238-KCurrent reportRestatement
- Mar 23, 20238-KCurrent reportAuditor change · Regulation FD disclosure
- Feb 2, 202310-QQuarterly report · period to Dec 2022
Official filings of MedMen with the US Securities and Exchange Commission.
Annual results
- Revenue
- $141 M
- Operating income
- $-169 M
- Net income
- $211 M
For year ending June-2022 · source: SEC filing
Balance sheet
- Total assets
- $321 M
- Total liabilities
- $636 M
- Total equity
- $160 M
As of June-2022
Insider trading at MedMen#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Melony ValleauCAO | Grant or award | +5.10 M | — | — | 5.10 M | Form 4 |
| filed | Amit PandeyCFO | Grant or award | +13.16 M | $0.020 | $263 K | 13.16 M | Form 4 |
| filed | Cameron Dovi SmithDirector | Grant or award | +143,449 | — | — | 984,022 | Form 4 |
| filed | Edward J. RecordDirector | Grant or award | +143,449 | — | — | 158,373 | Form 4 |
| filed | Errol SchweizerDirector | Grant or award | +106,028 | — | — | 1.23 M | Form 4 |
| filed | Melvin EliasDirector | Grant or award | +160,775 | — | — | 1.04 M | Form 4 |
| filed | David HsuDirector | Grant or award | +143,449 | — | — | 158,373 | Form 4 |
| filed | David HsuDirector | Grant or award | +14,924 | — | — | 14,924 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
MedMen scorecard#
Passes 3 of the 5 checks that could be worked out. Fiscal year 2021.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth1 of 1
- ✓Revenue grew in the newest year6.5%Revenue up 6.5% in fiscal 2021.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability2 of 2
- ✓Profitable in the newest year$211 MNet income $211 M in fiscal 2021.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianToo few peers for a median.
- ✓Return on equity above 15%119.9%119.9% in fiscal 2021.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 2
- ✗Short-term assets cover short-term liabilities0.5×Current ratio 0.51 at the end of fiscal 2021.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2021.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
MedMen: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2021to Jun 25, 2022 | FY 2020to Jun 26, 2021 | FY 2019to Jun 27, 2020 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 141+6.5%100% | 132r145−14.8%100% | 155—100% | |
| Cost of revenue | 71−0.6%50.5% | 72r78−28.4%54.1% | 100—64.4% | |
| Gross profit | 70+14.8%49.5% | 61r67+9.7%45.9% | 55—35.6% | |
| Selling and marketing | 3.2+219%2.3% | 1.0r1.1−90.6%0.8% | 11—6.9% | |
| General and administrative | 109−0.4%77.2% | 109r125−43.4%82.6% | 193—124% | |
| Operating expenses | 239+106%169% | 116r135−76.2%87.6% | 488—314% | |
| Operating income | −169—−120% | −55r−68—−41.7% | −432—−278% | |
| Net interest income | 32+4.2%23.0% | 31r37−9.3%23.5% | 34—22.1% | |
| Other non-operating income (expense) | 6.5−90.3%4.6% | 67r76+3.3%51.0% | 65—42.0% | |
| Income before tax | −166—−118% | −124r−145—−94.0% | −457—−294% | |
| Income tax | −9.9−640%−7.0% | 1.8—1.4% | −41—−26.4% | |
| Income from continuing operations | −166—−118% | −124r−145—−94.0% | −457—−294% | |
| Income from discontinued operations | −45—−32.2% | −12—−9.3% | −22—−13.9% | |
| Net income attributable to shareholders | 211+33.8%150% | 158−70.1%119% | 527—339% | |
| Shares, weighted average (basic) | — | 531+96.4%— | 270—— | |
| Shares, weighted average (diluted) | — | 531+96.4%— | 270—— | |
| Balance sheet | ||||
| Cash and cash equivalents | 11r11−1.0%3.6% | 12r12+20.6%2.4% | 9.6r10—1.7% | |
| Inventory | 10−37.5%3.1% | 16r20−22.5%3.4% | 21r23—3.6% | |
| Other current assets | 8.9r10.0+12.8%2.8% | 7.9r7.9−14.0%1.7% | 9.2r9.1—1.6% | |
| Current assets | 160r161−8.8%50.0% | 176r97+142%37.2% | 73r84—12.7% | |
| Property, plant and equipment | 64−40.1%20.0% | 107r138−35.5%22.7% | 166r175—28.9% | |
| Right-of-use (leased) assets | 43r48−30.6%13.4% | 62r77−38.4%13.1% | 100r116—17.5% | |
| Goodwill | 9.8r9.8−70.2%3.1% | 33r330.0%7.0% | 33r34—5.7% | |
| Other intangible assets | 41r36−50.9%12.8% | 83r115−40.4%17.7% | 140r148—24.4% | |
| Total assets | 321r323−32.1%100% | 472r472−17.7%100% | 574r574—100% | |
| Accounts payable | 33r39−26.9%10.3% | 45r57−40.9%9.6% | 77r75—13.3% | |
| Current liabilities | 314r326−9.5%97.8% | 347r289+89.6%73.4% | 183r189—31.8% | |
| Lease liabilities (non-current) | 51r44−18.0%15.9% | 62r100−46.4%13.2% | 116r131—20.2% | |
| Total liabilities | 636r642−12.4%198% | 726r726−3.3%154% | 751r751—131% | |
| Retained earnings | −897r−905—−280% | −717r−717—−152% | −631r−631—−110% | |
| Shareholders' equity | 160r152−16.6%49.9% | 192r192+19.9%40.6% | 160r−177—27.8% | |
| Minority interests | −475r−470—−148% | −445r−445—−94.3% | −337—−58.6% | |
| Total equity | −315r−319—−98.3% | −254r−254—−53.7% | −177r160—−30.8% | |
| Total liabilities and equity | 321r323−32.1%100% | 472r472−17.7%100% | 574r574—100% | |
| Cash-flow statement | ||||
| Depreciation and amortization | 26−9.9%18.2% | 28r34−29.7%21.5% | 41—26.1% | |
| Share-based compensation | 5.3−3.8%3.7% | 5.5−50.6%4.1% | 11—7.1% | |
| Cash from operating activities | −63—−44.4% | −59r−60—−44.9% | −110—−70.6% | |
| Capital expenditure | −9.0—−6.4% | −2.7r−6.9—−2.0% | −57—−37.0% | |
| Intangible assets bought | −0.6—−0.4% | −1.2r−0.9—−0.9% | −4.1—−2.7% | |
| Acquisitions, net of cash acquired | — | — | −0.6—−0.4% | |
| Cash from investing activities | −11−199%−7.7% | 11r11—8.3% | −19—−12.5% | |
| Cash from financing activities | 73+43.6%51.8% | 51−52.6%38.4% | 107—69.0% | |
| Report | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Mar 25, 2023 | Q3 FY2022to Mar 25, 2023 | Q2 FY2022to Dec 24, 2022 | Q1 FY2022to Sep 24, 2022 | Q4 FY2021to Jun 25, 2022 | Q3 FY2021to Mar 26, 2022 | Q2 FY2021to Dec 25, 2021 | Q1 FY2021to Sep 25, 2021 | Q4 FY2020to Jun 26, 2021 | Q3 FY2020to Mar 27, 2021 | Q2 FY2020to Dec 26, 2020 | Q1 FY2020to Sep 26, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||
| Revenue | 120−17.4%100% | 27−22.8%100% | 30−16.8%100% | 30−18.2%100% | 33r33*−12.4%100% | 35+10.1%100% | 36r39+9.0%100% | 37r40+4.6%100% | 38r49*—100% | 32—100% | 33r34—100% | 35—100% | |
| Cost of revenue | 60−20.2%49.8% | 14−22.0%51.7% | 15−17.8%49.1% | 15−21.5%50.6% | 16r16*−19.6%48.2% | 18−3.6%51.2% | 18r20+11.7%49.7% | 19r22+3.7%52.7% | 20r27*—52.5% | 19—58.4% | 16r16—48.5% | 19—53.1% | |
| Gross profit | 60−14.5%50.2% | 13−23.6%48.3% | 15−15.8%50.9% | 15−14.5%49.4% | 17r17*−4.4%51.8% | 17+29.2%48.8% | 18r19+6.5%50.3% | 17r17+5.6%47.3% | 18r22*—47.5% | 13—41.6% | 17r18—51.5% | 16—46.9% | |
| Selling and marketing | 2.2−30.5%1.8% | 0.6−43.5%2.1% | 0.6−45.3%1.9% | 0.4−25.2%1.5% | 0.6r0.6*+22.1%1.7% | 1.0+702%2.9% | 1.0r1.1+354%2.8% | 0.6r0.7+207%1.6% | 0.5r0.6*—1.3% | 0.1—0.4% | 0.2r0.2—0.7% | 0.2—0.6% | |
| General and administrative | 72−39.2%59.9% | 17−34.8%61.5% | 18−41.4%62.1% | 18−45.3%59.4% | 19r19*−33.8%57.3% | 26−11.2%72.9% | 31r35−1.6%88.1% | 33r36+8.0%88.9% | 29r35*—75.8% | 29—90.4% | 32r34—97.6% | 30—86.1% | |
| Operating expenses | 199+29.4%166% | 37−0.6%136% | 22−44.1%73.7% | 20r20−52.4%66.1% | 121r121*+234%362% | 37−7.1%106% | 39r44−10.7%110% | 42r46+298%114% | 36r42*—95.0% | 40—125% | 44r44—134% | 10—29.8% | |
| Operating income | −139—−116% | −24—−87.9% | −6.7—−22.8% | −5.0r−5.6—−16.6% | −103r−103*—−310% | −20—−57.0% | −21r−25—−59.5% | −24r−29−507%−66.2% | −18r−20*—−47.6% | −27—−83.8% | −27r−26—−82.5% | 6.0—17.0% | |
| Interest and finance income | — | — | — | — | — | — | — | — | — | — | −0.5—−1.7% | −0.0—−0.0% | |
| Net interest income | 35+20.4%29.3% | 10+28.3%37.0% | 9.7+19.9%32.8% | 10+23.0%33.5% | 5.4r5.4*+5.0%16.2% | 7.8−22.4%22.3% | 8.1r9.7+5.6%22.7% | 8.2r10.0−7.0%22.2% | 5.1r10*—13.5% | 10—31.6% | 7.7r10—23.5% | 8.8—25.0% | |
| Other non-operating income (expense) | 37+319%30.6% | 13—46.5% | 7.3—24.7% | 12+477%41.4% | 4.3*−63.9%13.0% | −0.6−103%−1.8% | −4.8r−2.2−137%−13.4% | 2.2r5.4−89.4%5.9% | 12r20*—31.5% | 23—70.9% | 13r20—39.9% | 20—57.8% | |
| Income before tax | −154—−128% | −37—−134% | −14—−47.5% | −17r−18—−58.0% | −86*—−259% | −19—−55.2% | −16r−23—−46.0% | −26r−34—−72.1% | −30r−40*—−78.4% | −50—−155% | −40r−46—−122% | −14—−40.8% | |
| Income tax | −24−309%−19.6% | −5.4−364982%−19.7% | 1.1—3.6% | 2.2−88.9%7.3% | −21r−21*—−64.4% | 0.0—0.0% | −8.1r−8.1−136%−22.9% | 20+60.3%53.6% | −0.3r−0.3*—−0.7% | −32—−101% | 23r24—69.2% | 12—35.0% | |
| Income from continuing operations | −152—−127% | −31—−115% | −15—−51.0% | −20r−20—−65.4% | −86r−86*—−259% | −19−442%−55.2% | −8.2—−23.1% | −46r−54—−126% | −30r−40*—−78.4% | 5.7r−5.2*—17.8% | −74*—−226% | −27—−75.8% | |
| Income from discontinued operations | 4.4—3.7% | −3.9—−14.2% | −2.3—−7.6% | 24r24—80.5% | −14r−14*—−40.9% | −11−239%−30.0% | −12r−5.5−1110%−34.2% | −1.2—−3.4% | −6.3*—−16.6% | 7.6—23.8% | 1.2—3.7% | −2.4—−6.8% | |
| Net income including minority interests | — | −35—−129% | −18r−17—−60.5% | 4.5r4.0—15.1% | — | −30—−85.2% | −20—−57.3% | −61—−165% | — | — | — | — | |
| Minority interests' share of net income | — | — | −1.1*—−3.7% | −0.0—−0.1% | — | — | — | — | — | — | — | — | |
| Net income attributable to shareholders | 272+64.8%226% | −31—−116% | −16—−54.8% | 4.6r4.2—15.2% | 315*+17.1%946% | −30—−84.4% | −19—−53.6% | −55r61−268%−151% | 269r269*—708% | −9.7—−30.4% | −69—−211% | 33—93.6% | |
| Shares, weighted average (basic) | 1,341+11.5%— | 1,341+11.5%— | 1,302+8.6%— | — | — | 1,202+122%— | 1,199+148%— | 943+123%— | — | 541—— | 483—— | 423—— | |
| Shares, weighted average (diluted) | 1,341+11.5%— | 1,341+11.5%— | 1,302+8.6%— | — | — | 1,202+122%— | 1,199+148%— | 943+123%— | — | 541—— | 483—— | 423—— | |
| Balance sheet | |||||||||||||
| Cash and cash equivalents | 7.6—3.5% | 7.6−47.1%3.5% | 16−67.3%6.5% | 21−73.0%8.4% | 11r11−1.0%3.6% | 14−32.4%3.3% | 48+532%9.7% | 78+704%14.7% | 12r12—2.4% | 21—4.4% | 7.5—1.5% | 9.7r10—1.8% | |
| Inventory | 15—6.8% | 15+22.9%6.8% | 14−34.0%5.7% | 9.1−53.0%3.6% | 10−37.5%3.1% | 12−30.0%2.8% | 21−18.7%4.2% | 19−8.9%3.6% | 16r20—3.4% | 17—3.5% | 25—5.1% | 21—4.0% | |
| Other current assets | 12—5.4% | 12+35.6%5.4% | 10+16.4%4.4% | 7.4−2.4%2.9% | 8.9r10.0+12.8%2.8% | 8.6+4.9%2.0% | 8.9+55.9%1.8% | 7.6−51.9%1.4% | 7.9r7.9—1.7% | 8.2—1.7% | 5.7—1.1% | 16—3.0% | |
| Current assets | 91—42.2% | 91−46.7%42.2% | 100−25.7%42.0% | 99−40.4%39.3% | 160r161−8.8%50.0% | 171+45.6%39.6% | 135+97.3%27.5% | 166+88.1%31.1% | 176r97—37.2% | 117—24.1% | 68—13.6% | 88—16.5% | |
| Property, plant and equipment | 52—24.3% | 52−42.8%24.3% | 58−57.2%24.2% | 60−55.6%23.9% | 64−40.1%20.0% | 92−31.6%21.2% | 135−11.7%27.4% | 135−13.6%25.4% | 107r138—22.7% | 134—27.5% | 152—30.3% | 156—29.2% | |
| Right-of-use (leased) assets | 26—12.1% | 26−51.4%12.1% | 34−50.6%14.4% | 44−40.7%17.7% | 43r48−30.6%13.4% | 54−28.5%12.4% | 69−29.4%14.1% | 75−25.6%14.1% | 62r77—13.1% | 75—15.4% | 98—19.5% | 101—18.9% | |
| Goodwill | 9.8—4.6% | 9.8−70.2%4.6% | 9.8−70.2%4.1% | 9.8−70.2%3.9% | 9.8r9.8−70.2%3.1% | 33+0.1%7.6% | 33−2.8%6.7% | 33−2.8%6.2% | 33r33—7.0% | 33—6.8% | 34—6.7% | 34—6.3% | |
| Other intangible assets | 33—15.1% | 33−54.7%15.1% | 33−69.6%13.7% | 34−69.4%13.6% | 41r36−50.9%12.8% | 72−37.6%16.6% | 108−19.5%21.9% | 111−19.5%20.9% | 83r115—17.7% | 115—23.7% | 134—26.5% | 138—25.9% | |
| Total assets | 216—100% | 216−50.1%100% | 238−51.4%100% | 251−52.8%100% | 321r323−32.1%100% | 432−11.4%100% | 491−2.5%100% | 532−0.4%100% | 472r472—100% | 487—100% | 504—100% | 534—100% | |
| Accounts payable | 44—20.4% | 44+18.3%20.4% | 43−20.9%18.0% | 35−39.0%14.1% | 33r39−26.9%10.3% | 37−36.1%8.6% | 54—11.1% | 58—10.9% | 45r57—9.6% | 58—11.9% | — | — | |
| Current liabilities | 474—220% | 474+26.4%220% | 238−27.1%99.7% | 234−32.3%93.0% | 314r326−9.5%97.8% | 375+32.7%86.8% | 326+47.9%66.4% | 345+74.3%64.9% | 347r289—73.4% | 283—58.0% | 220—43.8% | 198—37.1% | |
| Lease liabilities (non-current) | 40—18.5% | 40−27.5%18.5% | 41−57.1%17.1% | 47−51.8%18.8% | 51r44−18.0%15.9% | 55−43.1%12.7% | 95−18.3%19.4% | 98−15.0%18.4% | 62r100—13.2% | 97—19.9% | 116—23.1% | 115—21.6% | |
| Total liabilities | 573—266% | 573−15.6%266% | 567−20.1%238% | 565−23.0%225% | 636r642−12.4%198% | 679−4.3%157% | 710−5.4%145% | 733+0.9%138% | 726r726—154% | 710—146% | 750—149% | 727—136% | |
| Retained earnings | −941—−437% | −941—−437% | −910r−914—−381% | −893r−898—−355% | −897r−905—−280% | −821—−190% | −791—−161% | −772—−145% | −717r−717—−152% | −680—−139% | −674—−134% | −649—−122% | |
| Shareholders' equity | 122—56.8% | 122−40.5%56.8% | 151r146−35.7%63.2% | 165r161−34.2%65.8% | 160r152−16.6%49.9% | 206−3.5%47.6% | 234—47.7% | 251—47.2% | 192r192—40.6% | 213—43.7% | −247—−49.0% | −192—−36.0% | |
| Minority interests | −480—−223% | −480—−223% | −476r−475—−200% | −475r−474—−189% | −475r−470—−148% | −453—−105% | −454—−92.4% | −452—−85.0% | −445r−445—−94.3% | −435—−89.4% | −413—−81.9% | −360—−67.3% | |
| Total equity | −357—−166% | −357—−166% | −325r−329—−136% | −310r−314—−123% | −315r−319—−98.3% | −247r−247—−57.2% | −219r−219—−44.7% | −201—−37.8% | −254r−254—−53.7% | −222r−222—−45.6% | −247r166—−49.0% | −192r167—−36.0% | |
| Total liabilities and equity | 216—100% | 216−50.1%100% | 238r238−51.4%100.0% | 252r251−52.7%100% | 321r323−32.1%100% | 432−11.4%100% | 491−2.5%100% | 532−0.4%100% | 472r472—100% | 487—100% | 504—100% | 534—100% | |
| Cash-flow statement | |||||||||||||
| Depreciation and amortization | 14−27.1%11.7% | 1.2−56.6%4.4% | 1.4−56.0%4.8% | 4.0−36.5%13.2% | 7.4r7.4*+6.4%22.3% | 2.8−37.7%7.9% | 3.2r3.9−46.8%9.0% | 6.3r7.6−22.5%17.0% | 7.0r8.6*—18.4% | 4.5—13.9% | 6.0—18.5% | 8.1—23.0% | |
| Share-based compensation | 4.9−14.0%4.1% | 1.0*+81.8%3.8% | 2.1*+198%7.2% | 0.9−72.2%2.9% | 0.9r0.9*−33.0%2.6% | 0.6r0.6*+57.6%1.6% | 0.7r0.7*−71.1%2.0% | 3.1+130%8.4% | 1.3r1.3*—3.4% | 0.4r0.4*—1.1% | 2.5*—7.5% | 1.3—3.8% | |
| Cash from operating activities | −20—−16.9% | −15*—−54.5% | 1.3*—4.3% | −9.6—−32.0% | 2.8r2.8*—8.5% | −15r−16*—−43.8% | −27r−26*—−75.8% | −23r−23—−62.5% | −13r−16*—−34.4% | −16r−13*—−50.1% | −12*—−37.2% | −18—−51.7% | |
| Capital expenditure | — | — | — | — | — | — | −3.9*—−11.1% | −3.2—−8.6% | — | −2.3*—−7.0% | −0.9*—−2.8% | −0.3—−0.8% | |
| Intangible assets bought | — | — | — | — | — | — | −0.0*—−0.1% | −0.5—−1.3% | −0.6r−0.3*—−1.5% | — | −1.8*—−5.6% | −0.1—−0.2% | |
| Acquisitions, net of cash acquired | — | — | — | — | — | — | — | — | — | — | −0.3*—−1.0% | 0—0.0% | |
| Cash from investing activities | 45—37.7% | 5.9*+107%21.8% | −6.0*—−20.2% | 51—171% | −6.2r−6.2*—−18.5% | 2.9r2.9*+57.6%8.1% | −4.0r−4.0*−166%−11.1% | −3.6−137%−9.8% | −6.5r−3.7*—−17.2% | 1.8r−0.7*—5.7% | 6.0*—18.4% | 9.7—27.5% | |
| Debt issued | — | — | — | 20—65.1% | — | — | — | — | — | — | — | — | |
| Debt repaid | — | — | — | — | — | — | — | — | — | — | — | −0.3—−0.8% | |
| Cash from financing activities | −33−140%−27.5% | −0.4*—−1.5% | −0.8*—−2.7% | −32−134%−105% | −0.3r−0.3*−103%−0.8% | −20r−20*−169%−56.7% | −0.1r−0.1*−102%−0.2% | 93+981%254% | 10r10*—26.6% | 29r29*—90.1% | 3.2*—9.7% | 8.6—24.6% | |
| Change in cash | — | — | — | — | — | — | — | — | — | — | −2.8*—−8.5% | 0.2—0.6% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Mar 25, 2023. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at MedMen#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Financial statements withdrawn 1 · Auditor changed 1 · Debt called early 1 · Acquisition or sale completed 2 · Directors and officers 16 · Material agreement 4 · Agreement ended 1 · New debt 2 · Unregistered share sale 2 · Shareholder vote 2 · Results announced 3
| Filed | What happened | Filing |
|---|---|---|
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Acquisition or sale completed | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Financial statements withdrawn | 8-K | |
| Auditor changed | 8-K | |
| Acquisition or sale completed | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Debt called earlyDirectors and officersMaterial agreementNew debtUnregistered share sale | 8-K | |
| Directors and officersAgreement ended | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officersMaterial agreementNew debtUnregistered share sale | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Jan 30, 2024
Acquisitions and funding#
3 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Questions, comparisons and similar companies#
Questions people ask
Sources and freshness
- Annual results:
- For year ending June-2022
- Balance sheet:
- As of June-2022
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, Wikidata, Wikipedia, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at MedMen? Verify and update this profile — free
Show MedMen's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.